Q4 2025 Management View CEO David Endicott emphasized that "the second half of 2025 and especially the fourth quarter demonstrated the strength and momentum of our business." He highlighted recent ...

GENEVA--(BUSINESS WIRE)-- Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that UNITY® Vitreoretinal Cataract System ...

“Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us ...

Alcon on Tuesday forecast 2026 sales growth largely in line with market estimates and guided for a significant expansion in ...

I reiterate a 'Strong Buy' rating for Alcon with a one-year price target of $115 per share, driven by new product pipelines and FDA clearances. Alcon's Unity VCS/CS systems received FDA clearance, set ...

Implantables net sales were $474 million, an increase of 4%. Excluding favorable currency impacts of 2%, Implantables net sales increased 2% constant currency. This growth reflects strong performance ...

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, announced results from time and motion studies demonstrating superior efficiency* with UNITY® ...

Combined vitreoretinal-cataract system (VCS) is cleared for use in Canada New, proprietary technology is designed to deliver significant surgical and workflow efficiencies First innovation to be ...